• Species Reactivity
  Human
• Specificity
  Detects human Pentraxin 2/SAP in ELISA and Western Blot.
• Source
  Monoclonal Mouse IgG_2B Clone # 910119
• Purification
  Protein A or G purified from hybridoma culture supernatant
• Immunogen
  Mouse myeloma cell line NS0-derived recombinant human Pentraxin 2/SAP
  His20-Val233
  Accession # P02743
• Formulation
  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Label
  Unconjugated

• Western Blot
  0.5 µg/mL
  See below

• Reconstitution
  Reconstitute at 0.5 mg/mL in sterile PBS.
• Shipping
  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
• Stability & Storage
  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

• References:
  1. Goodman, A. et al. (1996) Cytokine Growth Factor Rev. 7:191.
  2. Steel, D. and A. Whitehead (1994) Immunol. Today 15:81.
  3. Hirschfield, G.M. and P.N. Hawkins (2003) Int. J. Biochem. Cell Biol. 35:1608.
  4. Emsley, J. et al. (1994) Nature 367:338.
  5. Mantzouranis, E. et al. (1985) J. Biol. Chem. 260:7752.
  6. Botto, M. et al. (1997) Nature Medicine 3:855.
  7. Pepys, M. et al. (2002) Nature 417:254.
  8. Bharadwaj, D. et al. (2001) J. Immunol. 166:6735.
• Long Name:
  Serum Amyloid P Component
• Entrez Gene IDs:
  325 (Human); 20219 (Mouse); 29339 (Rat)
• Alternate Names:
  9.5S alpha-1-glycoprotein; amyloid P component, serum; APCS; MGC88159; Pentraxin 2; PTX2; PTX2serum amyloid P-component; SAP; SAPpentaxin-related

Background:

Pentraxin 2 (PTX2), also known as Serum Amyoid P Component (SAP), is a secreted serum glycoprotein that is a universal non-fibrillar component of amyloid deposits. These extracellular deposits of insoluble protein fibrils are the result of protein misfolding and can lead to tissue damage and disease (1, 2). PTX2 belongs to the pentraxin (pentaxin) superfamily, whose members have the characteristic pentagonal discoid arrangement of five non-covalently bound subunits. Pentraxins bind to a variety of molecules in a calcium-dependent lectin-like manner through a pattern-recognition-binding site (1, 4, 5). There are two known subfamilies of pentraxins, the classical or short pentraxin subfamily that includes the serum C-reactive Protein (CRP) and PTX2, and the fusion or long pentraxin subfamily whose members contain pentraxin-related carboxyl-terminal halves (1).

PTX2 and CRP share approximately 50% amino acid sequence identity (2, 5). They are produced and secreted by liver hepatocytes and circulates in plasma. Mouse PTX2 is a major acute-phase protein whose plasma concentrations increase dramatically during an acute phase response (2). In human where CRP is the major acute-phase protein, the plasma concentration of human PTX2 remains relatively constant in response to tissue-damage (2, 5).

PTX2 associates ubiquitously with all amyloid deposits that are implicated in a diverse range of diseases including Alzheimer’s and prion diseases, type 2 diabetes and various systemic amyloidoses (3, 6, 7). As a non-fibrillar component, PTX2 regulates the solubility of amyloid fibrils and protects them from degradation by proteolytic enzymes and phagocytic cells. In addition to its role in the pathogenesis of amyloidoses, PTX2 also has an important physiological function in innate immunity (8).

      R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。  1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。  天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。  2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。